INTRODUCTION

Hyperlipidemia is a symptom associated with numerous health problems and reduced life expectancy (Bin-Jumah, 2018; Horton, Goldstein, & Brown, 2002). There is increasing evidence that hyperlipidemia is closely linked to chronic inflammation, which can lead to cardiovascular disease, fatty liver disease, and type 2 diabetes (Feuerer et al., 2009; Hoyt, Burnette, & Auster-Gussman, 2014). Altered gut microbiota composition has been linked to the development of hyperlipidemia and cardiometabolic diseases (Chan et al., 2016). A healthy intestinal environment comprises host and microbial factors, and relies on a functionally intact intestinal barrier and stable microbiota composition (Lu et al., 2016; Monk et al., 2019; Ojo et al., 2016). However, studies suggest that high-fat diets (HFDs)
may cause gut microbiota dysbiosis and intestinal integrity destruction. This process may cause an increase in blood lipopolysaccharide (LPS) concentration and was shown to increase inflammation in mice due to the activation of toll-like receptor 4 (TLR4)-mediated inflammation (Perry et al., 2016; Rooks & Garrett, 2016; Schroeder & Backhed, 2016). These findings indicate that HFD-induced hyperlipidemia in mice could be reversed by restoring the gut microbiota and intestinal barrier.

The available drugs for hyperlipidemia treatment include statins and fibrates, but these have side effects and are expensive, and have shown very limited effectiveness (Bin-Jumah, 2018; De Leo et al., 2005; Lee, Chun, Kwon, Kim, & Nam, 2017). Many researchers have also investigated and developed substances with lipid-lowering functions from natural products. The habitual consumption of foods with antilipid metabolism disorder effects may be an effective and manageable way to prevent hyperlipidemia.

Blue-green algae (BGA) are one of earth’s most primitive life forms and have been utilized in Asian food and medicine for several millennia (Johnson et al., 2008). Species such as Nostoc flagelliforme Born. et Flah, Spirulina platensis, and Nostoc sphaeroides Kütz (NO) contain a wide range of bioactive compounds and have various functions (Chen, Juneau, & Qiu, 2007). N. sphaeroides Kütz, also known as Ge-Xian-Mi in China, has been used as a health product for centuries (Hao et al., 2011; Ku et al., 2013). N. sphaeroides Kütz is high in polysaccharide, amino acid, protein, vitamin, and mineral contents (Yang et al., 2011), and has bioactive properties, including antiviral, antitumor, antidiabetic, anti-inflammatory, and lipid-modulating activities (Ku, Kim, Pham, Yang, Wegner, et al., 2015; Ku, Kim, Pham, Yang, Weller, et al., 2015; Ku et al., 2013). Previous studies have shown that N. sphaeroides Kütz and its extracts significantly reduced plasma TC and TG levels in male C57BL/6j mice and may reduce atherosclerosis risk (Ku, Kim, Pham, Yang, Weller, et al., 2015; Ku, Kim, Pham, Yang, Weller, et al., 2015; Ku et al., 2013). Nevertheless, the effects of N. sphaeroides Kütz on bodyweight and gut microbiota are unknown. Therefore, the understanding of the lipid-lowering mechanisms and anti-inflammatory effects of N. sphaeroides Kütz (NO) is a key to its application as a food supplement and in the food industry.

The present study aimed to explore the effects of NO supplementation on serum lipid levels, intestinal inflammation, integrity of the intestinal barrier, and gut microbiota associated with a HFD.

## 2 | EXPERIMENT METHODS

### 2.1 | Chemicals and reagents

N. sphaeroides Kütz (NO) used in this study was provided by Hunan Yandi Bioengineering Co., Ltd. Dry NO was crushed into powder at –20°C for 2 hr and then used directly in experiments. The main dry components of the NO used in the present research were fiber (47.3%), protein (30.8%), moisture (5.54%), and ash (5.7%); remaining components were vitamins and minerals. Components were identified by Societe Generale de Surveillance S.A. Assay kits of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were acquired from Nanjing Jiancheng Bioengineering Institute. ELISA kits for tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10) were purposed from Wuhan Hauimei Biological Engineering co. Ltd. Total RNA extraction reagent, SYBR Green Master primer, and oligo(dT)18 were obtained from Roche.

### 2.2 | Animals

Forty C57BL/6j male mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. at 6 weeks of age and were allowed to acclimate to their surroundings for 1 week. All mice were housed in an air-conditioned room (temperature 22°C ± 2°C) with a relative humidity of 50%–60% and 12-hr light/dark cycle.

### 2.3 | Experimental protocols

All animal procedures were in accordance with the Animal Care and Use Committee of Beijing Union University. At the end of adaptive feeding for 1 week, mice were randomly divided into four groups (n = 10 in each group, one animal per cage): the control group, the model group, the low-dose group, and high-dose group. Control group animals received an AIN-93M control diet, while other groups were fed a modified high-fat diet (HFD) based on AIN-93M for 4 weeks. During weeks 5–10, control group animals were maintained on a control diet, the model group was fed an HFD, the low-dose group was fed an HFD supplemented with 2.5% NO (w/w, 2.5% NO), and the high-dose group was fed with HFD supplemented with 7.5% NO (w/w, 7.5% NO). All feed was provided by Beijing Keao Xieli Feed Co., Ltd. (Beijing, China). Dietary compositions are shown in Table 1. At week 4, blood samples were collected by retro-orbital bleeding and transferred into centrifuge tubes. Serum samples were obtained by centrifugation at 4°C and 4,000 r/min for 10 min, and then stored at −80°C for further analysis. At the end of the experiment, mice were fasted for 16 hr. The following day, animals were weighed and anesthetized by intraperitoneal injection of barbital at 9:00 a.m. Blood samples were collected by orbital vein puncture. Intestinal tissue was collected and stored at −80°C for quantitative real-time reverse-transcription PCR (qRT-PCR).

### 2.4 | Biochemical analysis in serum

Serum lipid analysis was performed as described previously (Kang, Pichlah, Abinaya, Sohn, & Cha, 2016). Serum concentrations of TC, TG, HDL-C, and LDL-C were determined using commercial assay kits (Nanjing Jiancheng Bioengineering Institute). Serum concentrations TNF-α, IL-1β, IL-6, and IL-10 were determined using ELISA.
## TABLE 1  Composition of assay diets

| Ingredient          | Control diet |          | HFD |          | 2.5% NO |          | 7.5% NO |          |
|---------------------|--------------|----------|-----|----------|---------|----------|---------|----------|
|                     | g kcal       | g kcal   | g kcal | g kcal   | g kcal | g kcal   | g kcal | g kcal   |
| Cornstarch          | 465.7 1862.8 | 235.7 942.8 | 228.1 912.3 | 213.8 855.1 |
| Casein              | 140 560      | 110 440  | 107.6 430.3 | 103.0 412.2 |
| Dextrinized cornstarch | 155 620    | 155 620  | 151.6 606.4 | 145.2 580.8 |
| Sucrose             | 100 400      | 100 400  | 97.8 391.2  | 93.7 374.7  |
| Soybean oil         | 40 360       | 40 360   | 39.1 352.1  | 37.5 337.2  |
| Choline bitartrate  | 2.5 0        | 2.5 0    | 2.4 0    | 2.3 0    |
| Fiber               | 50 0         | 50 0     | 48.9 0    | 46.8 0    |
| Mineral mix         | 35 0         | 35 0     | 34.2 0    | 32.8 0    |
| Vitamin mix         | 10 40        | 10 40    | 9.8 39.1  | 9.4 37.5  |
| L-Cysteine          | 1.8 7.2      | 1.8 7.2  | 1.8 7.0  | 1.7 6.7  |
| Lard                | 0 0          | 150 1350 | 146.7 1320.3 | 140.5 1264.6 |
| Cholesterol         | 0 0          | 10 90    | 9.8 88.0  | 9.4 84.3  |
| Egg                 | 0 0          | 100 900  | 97.8 880.2 | 93.7 843.1 |
| NO powder           | 0 0          | 0 0      | 24.4 30.1  | 70.3 86.6  |
| Total               | 1,000 3,850  | 1,000 5,150 | 1,000 5,057.0 | 1,000 4,882.8 |

Note: 1: Solka-Floc cellulose. 2: AIN-93 mineral mix. 3: AIN-93 vitamin mix.

A total kilocalorie of NO was calculated based on the amounts of kilocalories in proteins (30.8%) as multiplying the amount of protein grams by four.

## TABLE 2  Primer pairs used for the real-time quantitative PCR analysis

| GenBank ID   | Gene name | Primer sequence (5’ to 3’) |
|--------------|-----------|----------------------------|
| NM_007393.3  | β-actin   | Forward GTGACGTTGACATCCGTAAGA | Reverse GTAACAGTCCGCTAGAAGCAC |
| NM_001278601.1 | TNF-α | Forward GCATCCAGCTTCAAATCTCGC | Reverse TGTCATCTCGGAGCGCTAGTG |
| NM_008361.4  | IL-1β     | Forward CCCTCACACTCAAACACC  | Reverse CTTTGAGATCCATGCGCTTG |
| NM_031168.2  | IL-6      | Forward CCCCAATTCCATGCTCTCC | Reverse CGCACTAGCTTGGCCGAGTA |
| NM_010548.2  | IL-10     | Forward TTTAGGGTTACTTGGGTGCC | Reverse AATGCTTCTTGTATTCTGGGC |
| NM_021297.2  | TLR4      | Forward TGAAGACTTTGGAATGAGA | Reverse CTGCCATTTTGGGGAATCTCAT |
| NM_009045.4  | NF-kB     | Forward AAGCACAGATAACACAAAGAC | Reverse CGCACTAGCTTCAAGTCTAGTC |
| NM_009386.2  | ZO-1      | Forward CTGGCAAGGAGGATAGGTG | Reverse CCCATCTCTTGGCAAAACTATC |
| NM_016674.4  | Claudin-1 | Forward ATGGATGAGCTGACATGG | Reverse GGACAGGAGGAGAAGAGTGG |
| NM_008756.2  | Occludin  | Forward GAGAGACTTTGACATGGGAAT | Reverse CGTCTGCTATAATCTCCCACC |
2.5 | Quantitative real-time reverse-transcription PCR

Total RNA from mouse tissue was extracted using a total RNA extraction kit (Servicebio) according to the manufacturer’s protocol. Two micrograms of total RNA samples were used to synthesize cDNA using a Revert Aid First-Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative real-time reverse-transcription PCR (qRT-PCR) was performed in triplicate using SYBR Green and a LightCycler 480 Real-Time PCR System (Roche Diagnostics). Each well was loaded with a 20 µl sample, containing 2.5 µl cDNA, 2.0 µl target primers, 8.0 µl water, and 12.5 µl Kapa SYBR Fast Master Mix. Hot-start PCR was performed for 40 cycles. Each cycle consisted of denaturation for 15 s at 95°C, annealing for 30 s, and elongation for 30 s at 60°C. Roche LightCycler software (version 1.5.0, Roche Diagnostics) was used for data analysis. The results were analyzed using the $2^{-\Delta \Delta Ct}$ method of analysis. Mean expression levels for control group mice were set as 100%. The primers used are shown in Table 2.

2.6 | Sequence processing and diversity analysis

Cecal fecal samples were snap-frozen in liquid nitrogen before storage at −80°C. Fecal DNA was extracted using a DNA isolation kit (Servicebio). The extracted DNA was amplified using primers targeted to the V3-V4 region of the bacterial 16S RNA gene (341F: CCTAYGGGRBGCASCAG; 806R: GGACTACNNGGGTATCTAAT). Sequencing was performed by Novogene Biotechnologies Inc. using an Illumina HiSeq 2500 sequencer. The raw reads were quality filtered by the UCHIME algorithm, and clean reads were used for analysis. Clean reads were clustered into operational taxonomic units (OTUs) according to the Ribosomal Database Project database based on 97% sequence similarity using Uparse software (version 7.0.1001). Alpha diversity analysis (Shannon index, Simpson index, and Good’s coverage) was performed using Qime software (version 1.9.1). Beta diversity analysis involved in principal coordinate analysis (PCoA) and nonmetric multidimensional scaling (NMDS) was calculated using R software according to the relative abundance of microbiota at the OTU level.

2.7 | Short-chain fatty acid analysis in mice cecal fecal

Cecal fecal samples were collected from each mouse and snap-frozen in liquid nitrogen before storage at −80°C. The concentration of short-chain fatty acids (SCFAs; acetic, propionic, and butyric acids) were measured by gas chromatography (GC). The GC instrument (FuLi 9720) was fitted with an FFAP column (30 m 0.25 mm 0.25 µm, Agilent) with a flame ionization detector. An internal standard was used crotonic acid.

2.8 | Statistical analysis

Statistical analysis was conducted using SPSS software for windows (version 22). Data were assessed by one-way ANOVA and Newman–Keuls pairwise comparison. $p$ values < .05 were considered significant differences. All data from assays are shown as mean ± SEM.

3 | RESULTS

3.1 | Bodyweight and food intake

Animal weights and food intake were monitored weekly. The initial bodyweights between groups were not significantly different. After 4 weeks of HFD, animals showed a significant increase ($p < .05$) in bodyweight compared with the control group (Figure 1a). Growth curves for the 10 weeks are shown in Figure 1b and c. It can be observed that HFD feeding for 10 weeks led to a significant increase in bodyweight ($p < .05$), while supplementation with NO prevented the bodyweight gain induced by HFD (Figure 1b and c). Mean daily food intake values are shown in Figure 1d. There was no significant difference among the four groups in daily food intake, indicating that the effects of NO on reducing bodyweight were not due to reduced food consumption.

3.2 | NO ameliorated lipid metabolic disorders

The effects of NO on serum lipid levels, including TC, TG, HDL, and LDL, were investigated. The levels of serum lipid increased significantly ($p < .05$) after 4 weeks of the HFD, indicating that hyperlipidemia model animals were successfully built (Table 3). After 6 weeks of NO treatment, the levels of TC, TG, and LDL were less than model group, and HDL was higher in 7.5% NO group compared with model group ($p < .05$) (Table 4).

3.3 | NO reduced inflammation in HFD-fed mice

Studies have reported that HFD-fed mice produce higher levels pro-inflammatory cytokines, including TNF-$\alpha$, IL-1$\beta$, and IL-6, than those with a normal diet; in contrast, levels of the anti-inflammatory cytokine IL-10 are lower in HFD-fed mice (Lu et al., 2016; Nam et al., 2018; Osborn & Olefsky, 2012). Serum TNF-$\alpha$, IL-1$\beta$, IL-6, and IL-10 concentrations were measured in the present study. The mRNA expression of these cytokines was also measured in colon tissue. Serum TNF-$\alpha$, IL-1$\beta$, and IL-6 concentrations were higher in the model group mice, while IL-10 was lower in the model group mice ($p < .05$) (Table 5). In 7/5% NO group, TNF-$\alpha$, IL-1$\beta$, and IL-6 expression levels...
were higher in model group animals, while IL-10 expression level was lower ($p < .05$) (Figure 2a–f). Notably, the colon tissue mRNA expression levels of these cytokines were inversely correlated with the concentration of NO. The colon tissue expression levels of TNF-$\alpha$, IL-1$\beta$, and IL-6 were less than model group, and IL-10 mRNA expression level was higher in the 2.5% and 7.5% NO group compared with the model group ($p < .05$). Expression levels of these cytokines in the 2.5% and 7.5% NO groups were closer to those of control group mice than HFD-fed mice (Figure 2a–d).

TLR4 signaling serves to initiate inflammation, controls the production of inflammatory cytokines in target tissues, and leads to chronic inflammation in HFD-fed mice (Chan et al., 2016; Chang et al., 2015). TLR4 signaling pathways also initiate inflammation by modulating the activity of NF-kB (Hoang et al., 2011). Therefore, the effects of NO on TLR4 and NF-kB mRNA expression in colon tissue were examined in the present study. As shown in Figure 3e and f, the mRNA expression levels of TLR4 and NF-kB were higher in model group animals compared with control group ($p < .05$). Mice treated with 2.5% and 7.5% NO had lower expression levels of TLR4 and NF-kB than HFD mice without NO treatment ($p < .05$). Therefore, results suggest that NO reduced inflammation levels by modulating TLR4-initiated NF-kB signal cascades.
The effect of NO treatment on fecal microbiota structure was assessed by 16S rRNA (V3-V4 region) sequencing of cecal fecal samples. A total of 1,464,817 raw reads were obtained. After selecting effective sequences, a total of 1,374,732 clean reads and an average of 68,736 ± 9,812 effective reads in each sample (n = 5 for each group) were generated. Shannon and Simpson index were used to analyze the sequencing diversity; the bacterial phylotype richness was reflected by ACE and Chao1 index. Species diversity and richness for each group are shown in Table 6. Sequencing diversity showed no significant difference between each group, while Chao1 and ACE index were much lower in the model group animals (Table 6). The degrees of OTUs shared in four groups are represented in Figure 3a. A total of 375 OTUs were common for all groups (Figure 4), while unique OTUs were also exhibited by each group (10 for the control group, 14 for the model group, 20 for the 2.5% NO group, and 23 for the 7.5% NO group, respectively), indicating greater OTU diversity in NO-supplemented groups. Principal coordinate analysis (PCoA) and nonmetric multidimensional scaling (NMDS) based on weighted UniFrac distance revealed a clear clustering of microbiota composition for each group (Figure 4b and c). Both 2.5% and 7.5% NO groups aggregated closer to the control group than the model group (Figure 4b and c). Table 7 shows the results of Adonis analysis. From R² value and p value, we could conclude that the results of PCoA and NMDS are reliable.

Taxonomic analysis revealed the dominant species in gut microbiotas at different levels. Notably, at the phylum level, model group animals showed a higher level in Firmicutes and lower level in Bacteroidetes compared with other groups (Figure 5a) and showed a significant difference compared with other groups (Figure 5c). According to previous studies, the abundance of Firmicutes often showed higher level and Bacteroidetes lower level in HFD-fed mice. Supplementation with NO reversed this situation (Figure 5a). At the order level, consistent with the phylum level, Bacteroidales showed a lower level in the model group, while NO groups showed higher level of Bacteroidales (Figure 5b). Erysipelotrichales are a class of Firmicutes; these showed higher level in Firmicutes and lower level in Bacteroidetes compared with other groups (Figure 5a). While protected by NO treatment, the mRNA expression of tight junction components involved in zonula occludens-1 (ZO-1), claudin-1, and occludin in the mouse intestine. The mRNA expression levels of ZO-1, claudin-1, and occludin were less than other groups in model group animals (Figure 3a–c). This result is consistent with that of a previous study, which showed that HFD feeding may affect gut permeability (Monk et al., 2019). While protected by NO treatment, the mRNA expression of ZO-1, claudin-1, and occludin in the mouse intestine. The mRNA expression levels of ZO-1, claudin-1, and occludin increased, especially in 7.5% NO group animals (Monk et al., 2019). While protected by NO treatment, the mRNA expression of tight junction components involved in zonula occludens-1 (ZO-1), claudin-1, and occludin increased, especially in 7.5% NO group animals.

### 3.4 | NO maintained intestinal integrity in HFD-fed mice

Previous studies have shown that HFD may affect intestinal epithelial barrier permeability (Baye, Guyot, & Mouquet-Rivier, 2017; Wu et al., 2017). We examined the mRNA expression of tight junction components involved in zonula occludens-1 (ZO-1), claudin-1, and occludin in the mouse intestine. The mRNA expression levels of ZO-1, claudin-1, and occludin were less than other groups in model group animals compared with other groups (Figure 3a–c). These results suggest that NO may have protective effects on intestinal barrier integrity in mice.

### 3.5 | NO regulated HFD-induced gut dysbiosis

The effect of NO treatment on fecal microbiota structure was assessed by 16S rRNA (V3-V4 region) sequencing of cecal fecal samples. A total of 1,464,817 raw reads were obtained. After selecting effective sequences, a total of 1,374,732 clean reads and an average of 68,736 ± 9,812 effective reads in each sample (n = 5 for each group) were generated. Shannon and Simpson index were used to analyze the sequencing diversity; the bacterial phylotype richness was reflected by ACE and Chao1 index. Species diversity and richness for each group are shown in Table 6. Sequencing diversity showed no significant difference between each group, while Chao1 and ACE index were much lower in the model group animals (Table 6). The degrees of OTUs shared in four groups are represented in Figure 3a. A total of 375 OTUs were common for all groups (Figure 4), while unique OTUs were also exhibited by each group (10 for the control group, 14 for the model group, 20 for the 2.5% NO group, and 23 for the 7.5% NO group, respectively), indicating greater OTU diversity in NO-supplemented groups. Principal coordinate analysis (PCoA) and nonmetric multidimensional scaling (NMDS) based on weighted UniFrac distance revealed a clear clustering of microbiota composition for each group (Figure 4b and c). Both 2.5% and 7.5% NO groups aggregated closer to the control group than the model group (Figure 4b and c). Table 7 shows the results of Adonis analysis. From R² value and p value, we could conclude that the results of PCoA and NMDS are reliable.

### 3.6 | The effects of NO on cecal fecal SCFAs in HFD-fed mice

The main SCFAs (acetic, propionic, and butyric acids) in cecal fecal were determined by gas chromatography. The concentrations of acetic and propionic acids showed no significant difference among the 4 groups (Figure 6a and b). The levels of butyric acids were higher in the model group animals compared with other groups (Figure 6c).
Although previous studies have reported that *N. sphaeroids kutz* lowered serum TC and TG and produced beneficial effects in hyperlipidemia mice, the effects of NO on the intestinal inflammation and gut microbiota have not been reported. In the present study, the effects of NO supplementation on HFD-induced mice were assessed. Results showed that NO reversed dietary-induced obesity, relieved intestinal inflammation, altered the gut microbiota, and protected intestinal integrity.

The current model of HFD-induced chronic inflammation induced based on the dysbiosis of the gut microbiota and increased levels of blood lipopolysaccharide (LPS), also called metabolic endotoxemia (Cani et al., 2009). As seen in HFD-fed animals, when...
the intestinal tube is in a state of dysbiosis it may gradually become leaky, allowing the LPS to enter enterohepatic circulation. Low blood concentrations of LPS blood may cause systemic and targeted inflammation in HFD-fed mice through activation of TLR4 signaling in cells (Anhe et al., 2018). Results from the present study indicate that NO supplementation inhibited TLR4 gene expression and decreased inflammation in HFD-fed mice. NO treatment also improved gut barrier integrity. The beneficial effects associated with NO treatment may therefore be attributed to specific alterations in the gut microbiota and the maintenance of gut barrier integrity.

The current study has shown that NO treatment led to remarkable changes in the gut microbiota composition, which partially improved the dysbiosis of microbiota induced by HFD. Results indicate that the gut microbiota can be changed by an HFD, and also modulated by dietary intervention. Therefore, NO may be used as a raw material in functional food to encourage gut microbiotas associated with reduced weight gain, inflammation, and disruption of

---

**TABLE 6** Alpha diversity in different groups

| Group     | Control | Model | 2.5% NO | 7.5% NO |
|-----------|---------|-------|---------|---------|
| Shannon   | 5.25 ± 0.29 | 4.68 ± 0.94 | 4.98 ± 0.65 | 4.78 ± 0.18 |
| Simpson   | 0.94 ± 0.016 | 0.86 ± 0.11 | 0.91 ± 0.067 | 0.92 ± 0.01 |
| Chao1     | 268.97 ± 21.95 | 177.56 ± 21.95<sup>a</sup> | 250.31 ± 32.65<sup>ab</sup> | 259.67 ± 19.81 |
| ACE       | 275.50 ± 18.73<sup>a</sup> | 210.60 ± 31.86<sup>b</sup> | 256.60 ± 14.88<sup>ab</sup> | 253.18 ± 32.64<sup>ab</sup> |

Note: Values represent mean ± SEM, n = 5 in each group. The superscript different letters represent statistically significant (p < .05), whereas the same letter suggests that there are no statistically significant differences between groups (p > .05).
the intestinal barrier in hyperlipidemia and obese animals. Previous studies have shown that the gut microbiotas of obese animals and humans are associated with increased levels of intestinal Firmicutes and decreased levels of Bacteroidetes, indicating that these two bacterial taxa may play an important role in hyperlipidemia in animals and humans (Makki, Deehan, Walter, & Backhed, 2018; Ojo et al., 2016; Schroeder & Backhed, 2016). A previous study suggested that feeding with plant hemicellulose can reverse a decrease in of Bacteroides-to-Firmicutes ratio and lead to weight loss (Koh, De Vadder, Kovatcheva-Datchary, & Backhed, 2016). In the present study, NO supplementation in HFD-fed mice led to a greater Firmicutes-to-Bacteroidetes ratio compared to model group mice (Figure 5a and b). Bifidobacterium spp. was previously reported to reduce obesity, but were not detected in the current study (Mathur & Barlow, 2015). Furthermore, Akkermansia was found to ease intestinal inflammation in another study (Everard, 2013). However, Akkermansia were not detected in NO-treated and model group mice in the present study. This observation suggests that NO may produce...
beneficial effects by altering the Firmicutes-to-Bacteroidetes ratio and altering the levels of other bacterial species related to lipid metabolism. The contents of acetic, propionic, butyric, and total acids were analyzed in the present study. The contents of acetic and propionic acids showed no significant differences among the 4 groups, while the levels of butyric showed higher level in the model group animals (Figure 6a–c). A previous study suggested that butyric acid is one of the main products of Bacteroidetes. In the present study, model group mice had the highest level of Bacteroidetes, so the butyric acid in the model group mice showed higher level. These results are consistent with a previous study, which showed that bacteria of the Firmicutes phyla mainly produce butyric acid and Bacteroides mainly produce acetic and propionic acids (Louis, Hold, & Flint, 2014).

5 | CONCLUSION

Notably, results showed that NO produced significant beneficial effects in HFD-fed mice. Collectively, the results suggest that NO may be used as an ingredient for functional foods to reduce body weight gain and chronic inflammation in hyperlipidemia and obese individuals.

ACKNOWLEDGMENTS

The authors are grateful to the facilities of Beijing Key Laboratory of Bioactive Substances and Functional Food.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

ETHICAL STATEMENT

The authors declare that there is no conflict of interests. All experiments were conducted in accordance with “The Instructive Notions with Respect to Caring for Laboratory Animals” issued by the Ministry of Science and Technology of the People’s Republic of China. The study’s protocols and procedures were ethically reviewed and approved by Beijing Union University animal experiment ethics review committee.
FIGURE 6  The effects of NO on cecal fecal SCFAs in HFD-fed mice. Values represent mean ± SEM n = 8 in each group. (a) Acetic acids. (b) Propionic acids. (c) Butyric acids. Letters represent statistically significant differences (p < .05). Instances of the same letter between groups indicate that no statistically significant difference was found between the groups (p > .05)

REFERENCES

Anhê, F. F., Varin, T. V., Le Barz, M., Pilon, G., Dudonné, S., Trottier, J., ... Marette, A. (2018). Arctic berry extracts target the gut-liver axis to alleviate metabolic endotoxaemia, insulin resistance and hepatic steatosis in diet-induced obese mice. Diabetologia, 61(4), 919–931. https://doi.org/10.1007/s00125-017-4520-z

Baye, K., Guyot, J. P., & Mouquet-Rivier, C. (2017). The unresolved role of dietary fibers on mineral absorption. Critical Reviews in Food Science and Nutrition, 57(5), 949–957. https://doi.org/10.1080/10408398.2014.953030

Bin-Jumah, M. N. (2018). Monolluma quadrangula protects against oxidative stress and modulates LDL receptor and fatty acid synthase gene expression in hypercholesterolemic rats. Oxidative Medicine and Cellular Longevity, 2018, 3914384. https://doi.org/10.1155/2018/3914384

Chan, Y. K., Brar, M. S., Kirjavainen, P. V., Chen, Y., Peng, J., Li, D., ... El-Nezami, H. (2016). High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: A pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE(-/-) mice. BMC Microbiology, 16(1), 264. https://doi.org/10.1186/s12866-016-0883-4

Chang, C.-J., Lin, C.-S., Lu, C.-C., Martel, J., Ko, Y.-F., Ojcius, D. M., ... Lai, H.-C. (2015). Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nature Communications, 6, 7489. https://doi.org/10.1038/ncomms8489

Deleo, M., Detommasi, N., Sanogo, R., Autore, G., Marzocco, S., Pizza, C., ... Braca, A. (2005). New pregnane glycosides from Caralluma dalzielii. Steroids, 70(9), 573–585. https://doi.org/10.1016/j.steroids.2005.03.013

Everard, A., Belzer, C., Geurts, L., Ouwkerk, J. P., Druart, C., Bindels, L. B., ... Cani, P. D. (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. PNAS, 110(22), 9066–9071.
Feurer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., ... Mathis, D. (2009). Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. *Nature Medicine*, 15(8), 930–939. https://doi.org/10.1038/nm.2002

Hao, Z., Li, D., Li, Y., Wang, Z., Xiao, Y., Wang, G., ... Liu, Q. (2011). Nostoc sphaeroides Kützing, an excellent candidate producer for C6LSS. *Advances in Space Research*, 48(10), 1565–1571. https://doi.org/10.1016/j.asr.2011.06.035

Hoang, M.-H., Houn, S.-J., Jun, H.-J., Lee, J.-H., Choi, J.-W., Kim, S.-H., ... Lee, S.-J. (2011). Barley intake induces bile acid excretion by reduced expression of intestinal ASBT and NPC1L1 in C57BL/6J mice. *Journal of Agriculture and Food Chemistry*, 59(12), 6798–6805. https://doi.org/10.1021/jf200681n

Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002). SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. *Journal of Clinical Investigation*, 109(9), 1125–1131. https://doi.org/10.1172/jci021593

Hoyt, C. L., Burnette, J. L., & Auster-Gussman, L. (2014). “Obesity is a disease”: Examining the self-regulatory impact of this public-health message. *Psychological Science*, 25(4), 997–1002. https://doi.org/10.1177/0956797613516981

Johnson, H. E., King, S. R., Banack, S. A., Webster, C., Callanaupa, W. J., & Cox, P. A. (2008). Cyanobacteria (Nostoc commune) used as a dietary item in the Peruvian highlands produce the neurotoxic amino acid BMAA. *Journal of Ethnopharmacology*, 118(1), 159–165. https://doi.org/10.1016/j.jep.2008.04.008

Kang, H. J., Pichiahi, P. T., Abinaya, R. V., Sohn, H. S., & Cha, Y. S. (2016). Hypocholesterolemic effect of quercetin-rich onion peel extract in C57BL/6J mice fed with high cholesterol diet. *Food Science and Biotechnology*, 25(3), 855–860. https://doi.org/10.1007/s10068-016-0141-4

Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Backhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*, 165(6), 1332–1345. https://doi.org/10.1016/j.cell.2016.05.041

Ku, C. S., Kim, B., Pham, T. X., Yang, Y., Wegner, C. J., Park, Y.-K., ... Lee, J.-Y. (2015). Blue-green algae inhibit the development of atherosclerotic lesions in apolipoprotein E knockout mice. *Journal of Medicinal Food*, 18(12), 1299–1306. https://doi.org/10.1089/jmf.2015.0025

Ku, C. S., Kim, B., Pham, T. X., Yang, Y., Weller, C. L., Carr, T. P., ... Lee, J. Y. (2015). Hypolipidemic effect of a blue-green alga (Nostoc commune) is attributed to its nonlipid fraction by decreasing intestinal cholesterol absorption in C57BL/6J mice. *Journal of Medicinal Food*, 18(11), 1214–1222. https://doi.org/10.1089/jmf.2014.0121

Ku, C. S., Pham, T. X., Park, Y., Kim, B., Shin, M. S., Kang, I., & Lee, J. (2013). Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-kappaB pathway in macrophages and splenocytes. *Biochimica Et Biophysica Acta*, 1830(4), 2981–2988. https://doi.org/10.1016/j.bbadgen.2013.01.018

Lee, K. S., Chun, S. Y., Kwon, Y. S., Kim, S., & Nam, K. S. (2017). Deep sea water improves hypercholesterolemia and hepatic lipid accumulation through the regulation of hepatic lipid metabolic gene expression. *Molecular Medicine Reports*, 15(5), 2814–2822. https://doi.org/10.3892/mmr.2017.6317

Louis, P., Hold, G. L., & Flint, H. J. (2014). The gut microbiota, bacterial metabolites and colorectal cancer. *Nature Reviews Microbiology*, 12(10), 661–672. https://doi.org/10.1038/nrmicro3344

Lu, Y., Fan, C., Li, P., Lu, Y., Chang, X., & Qi, K. (2016). Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating g protein-coupled receptors and gut microbiota. *Scientific Reports*, 6, 37589. https://doi.org/10.1038/srep37589

Makki, K., Deehan, E. C., Walter, J., & Backhed, F. (2018). The impact of dietary fiber on gut microbiota in host health and disease. *Cell Host & Microbe*, 23(6), 705–715. https://doi.org/10.1016/j.chom.2018.05.012

Mathur, R., & Barlow, G. M. (2015). Obesity and the microbiome. *Expert Review of Gastroenterology & Hepatology*, 9(8), 1087–1099. https://doi.org/10.1586/17474124.2015.1051029

Monk, J. M., Wu, W., Lepp, D., Wellings, H. R., Hutchinson, A. L., Liddle, D. M., ... Power, K. A. (2019). Navy bean supplemented high-fat diet improves intestinal health, epithelial barrier integrity and critical aspects of the obese inflammatory phenotype. *Journal of Nutritional Biochemistry*, 70, 91–104. https://doi.org/10.1016/j.jnutbio.2019.04.009

Nam, M., Choi, M.-S., Choi, J.-Y., Kim, N., Kim, M.-S., Jung, S., ... Hwang, G.-S. (2018). Effect of green tea on hepatic lipid metabolism in mice fed a high-fat diet. *Journal of Nutritional Biochemistry*, 51, 1–7. https://doi.org/10.1016/j.jnutbio.2017.09.002

Ojo, B., El-Rassi, G. D., Payton, M. E., Perkins-veazie, P., Clarke, S., Smith, B. J., & Lucas, E. A. (2016). Mango supplementation modulates gut microbial dysbiosis and short-chain fatty acid production independent of body weight reduction in C57BL/6 mice fed a high-fat diet. *Journal of Nutrition*, 146(8), 1483–1491. https://doi.org/10.3945/jrn.115.226688

Osborn, O., & Olefsky, J. M. (2012). The cellular and signaling networks linking the immune system and metabolism in disease. *Nature Medicine*, 18(3), 363–374. https://doi.org/10.1038/nm.2627

Perry, R. J., Peng, L., Barry, N. A., Cline, G. W., Zhang, D., Cardone, R. L., ... Shulman, G. I. (2016). Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. *Nature*, 534(7606), 213–217. https://doi.org/10.1038/nature18309

Rooks, M. G., & Garrett, W. S. (2016). Gut microbiota, metabolites and host immunity. *Nature Reviews Immunology*, 16(6), 341–352. https://doi.org/10.1038/ni.2016.42

Schroeder, B. O., & Backhed, F. (2016). Signals from the gut microbiota to distant organs in physiology and disease. *Nature Medicine*, 22(10), 1079–1089. https://doi.org/10.1038/nm.4185

Wu, Q., Pi, X., Liu, W., Chen, H., Yin, Y., Yu, H. D., ... Zhu, L. (2017). Fermentation properties of isomaltooligosaccharides are affected by human fecal enterotypes. *Anaerobe*, 48, 206–214. https://doi.org/10.1016/j.anaerobe.2017.08.016

Yang, Y., Kim, B., Park, Y. K., & Lee, J. Y. (2014). Effects of long-term supplementation of blue-green algae on lipid metabolism in C57BL/6J mice. *Journal of Nutritional Health & Food Science*, 1(1), 1–6. https://doi.org/10.15226/jnhsf.2014.00108

Yang, Y., Park, Y., Cassada, D. A., Snow, D. D., Rogers, D. G., & Lee, J. (2011). In vivo and in vivo safety assessment of edible blue-green algae, Nostoc commune var. sphaeroides Kützing and Spirulina planifensis. *Food and Chemical Toxicology*, 49(7), 1560–1564. https://doi.org/10.1016/j.fct.2011.03.052

---

**How to cite this article:** Wei F, Liu Y, Bi C, Chen S, Wang Y, Zhang B. Nostoc sphaeroides Kütz ameliorates hyperlipidemia and maintains the intestinal barrier and gut microbiota composition of high-fat diet mice. *Food Sci Nutr*. 2020;8:2348–2359. [https://doi.org/10.1002/fsn3.1521](https://doi.org/10.1002/fsn3.1521)